NCT07125950 is a Phase 2 clinical trial of SHR2554 in Advanced Breast Cancer, sponsored by Henan Cancer Hospital.

Who is sponsoring NCT07125950?

NCT07125950 is sponsored by Henan Cancer Hospital.

What drugs are being tested in NCT07125950?

Interventions in NCT07125950: SHR2554, HRS-8080, HRS-1358.

What condition does NCT07125950 study?

NCT07125950 studies Advanced Breast Cancer.

Is NCT07125950 still recruiting?

NCT07125950 is currently not yet recruiting. Last updated 15 August 2025.

Last reviewed 2025-08-15 · How we verify

NCT07125950

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer

Not yet recruiting Phase 2 Last updated 15 August 2025

What this trial tests

Phase 2 trial testing SHR2554 in Advanced Breast Cancer in 60 participants. Not yet recruiting.

Timeline

30 September 2025

Primary endpoint
30 September 2027

31 January 2028

Quick facts

Lead sponsor	Henan Cancer Hospital
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	30 September 2025
Primary completion	30 September 2027
Estimated completion	31 January 2028
Sites	1 location across China

Drugs / interventions tested

SHR2554 — full drug profile →
HRS-8080 — full drug profile →
HRS-1358 — full drug profile →

Conditions studied

Advanced Breast Cancer — all drugs for Advanced Breast Cancer →

Sponsor

Henan Cancer Hospital

Who can join

Adults 18 to 75, any sex, with Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our study is aimed to evaluate the safety and preliminary of all-oral regimen SHR2554 combined with HRS-8080 or HRS-1358 in advanced breast cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Epigenetic modifications in cancer drug resistance: molecular mechanisms and therapeutic interventions.
Yang J, Zhang M, Zhong Y, Sun C, et al · · 2026 · PMID 42053742 · DOI 10.1186/s43556-026-00458-9

Verify or expand the search:

Other trials of SHR2554

Trials testing the same drug.

NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
NCT05592262 — Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects · Phase 1 · completed
NCT05559008 — A Umbrella Study in R/R PTCL Guided by Molecular Subtypes · Phase 1, PHASE2 · unknown
NCT04355858 — Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer · Phase 2 · unknown
NCT04335266 — A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects · Phase 1 · completed

Other recruiting trials for Advanced Breast Cancer

Currently open trials in the same condition.

NCT07408089 — Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer · Phase 1 · recruiting
NCT07318805 — A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
NCT07259226 — Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers · Phase 2 · recruiting
NCT06982521 — Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PI · Phase 3 · recruiting
NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting

Other Henan Cancer Hospital trials

Trials by the same sponsor.

NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07125950 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
Last refreshed: 15 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07125950.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing